Department of Anesthesiology, Emory University School of Medicine and Emory Healthcare, Atlanta, GA, USA.
J Thorac Cardiovasc Surg. 2012 May;143(5):1213-8. doi: 10.1016/j.jtcvs.2011.07.068. Epub 2012 Feb 11.
Patients recovering from cardiothoracic surgery are known to be at increased risk of heparin-induced thrombocytopenia. Postoperatively, if heparin-induced thrombocytopenia is suspected, heparin is discontinued immediately and an alternative anticoagulant, such as the direct thrombin inhibitor argatroban, is administered. Current data regarding the safety and efficacy of argatroban in the postoperative cardiothoracic surgical patient in the intensive care setting are limited.
Data were collected retrospectively from January 1, 2007, to December 31, 2010, from patients tested for antiplatelet factor 4/heparin antibodies on clinical suspicion of heparin-induced thrombocytopenia after cardiothoracic surgery. We evaluated the use of argatroban as a therapeutic agent for the postoperative treatment of suspected heparin-induced thrombocytopenia by comparing thrombotic and bleeding events, platelet dynamics, antiplatelet factor 4/heparin antibody titer, and clinical probability score between patients who did and did not receive argatroban.
Eighty-seven patients were included; 47 patients (54%) were treated with argatroban, and 40 patients (46%) were not treated with argatroban. There was no association between argatroban therapy and bleeding, mortality, length of stay, or pretreatment thrombotic events. Among all patients, antiplatelet factor 4/heparin antibody titer and clinical probability score were higher in patients treated with argatroban.
Clinical suspicion of heparin-induced thrombocytopenia as detected by clinical probability score and thrombotic complications should prompt immediate cessation of heparin and initiation of an alternative anticoagulant such as argatroban. The results from this study demonstrate that argatroban should be considered without increased risk for adverse events, including bleeding, in the cardiothoracic intensive care unit after surgery.
众所周知,进行心胸外科手术后的患者存在肝素诱导的血小板减少症的风险增加。如果怀疑发生肝素诱导的血小板减少症,术后应立即停止肝素,并使用替代抗凝剂,如直接凝血酶抑制剂阿加曲班。目前有关阿加曲班在重症监护环境下心胸外科手术后患者中的安全性和疗效的数据有限。
我们回顾性地收集了 2007 年 1 月 1 日至 2010 年 12 月 31 日期间因怀疑肝素诱导的血小板减少症而在心胸外科手术后进行血小板因子 4/肝素抗体检测的患者的数据。我们通过比较血栓形成和出血事件、血小板动力学、血小板因子 4/肝素抗体滴度和临床可能性评分,评估了阿加曲班在术后治疗疑似肝素诱导的血小板减少症中的治疗作用,比较了接受和未接受阿加曲班治疗的患者。
共纳入 87 例患者;47 例(54%)患者接受了阿加曲班治疗,40 例(46%)患者未接受阿加曲班治疗。阿加曲班治疗与出血、死亡率、住院时间或预处理血栓形成事件之间无关联。在所有患者中,接受阿加曲班治疗的患者的血小板因子 4/肝素抗体滴度和临床可能性评分均较高。
通过临床可能性评分和血栓并发症检测到肝素诱导的血小板减少症的临床怀疑,应立即停止肝素,并启动替代抗凝剂,如阿加曲班。本研究结果表明,在心胸外科手术后的重症监护病房中,应考虑使用阿加曲班,而不会增加出血等不良事件的风险。